A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Adjuvants, Immunologic
/ therapeutic use
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Dendritic Cells
/ immunology
Granuloma
/ immunology
HEK293 Cells
Healthy Volunteers
Humans
Killer Cells, Natural
/ immunology
Ligands
Male
Middle Aged
Peptides
/ therapeutic use
Toll-Like Receptor 1
/ immunology
Toll-Like Receptor 2
/ immunology
Vaccination
Adjuvant
Immunotherapy
Lipopeptide
TLR1/2 ligand
Vaccines
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
10
06
2019
accepted:
30
10
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
3
7
2020
Statut:
epublish
Résumé
We previously showed that the bacterial lipopeptide Pam We now designed a new water-soluble synthetic Pam Thus, in one volunteer we show a granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only. The ex vivo T cell responses in peripheral blood were detectable for more than one year and could be strongly boosted by a second vaccination. Hence, XS15 is a promising adjuvant candidate for peptide vaccination, in particular for tumor peptide vaccines in a personalized setting.
Sections du résumé
BACKGROUND
We previously showed that the bacterial lipopeptide Pam
CASE PRESENTATION
We now designed a new water-soluble synthetic Pam
CONCLUSION
Thus, in one volunteer we show a granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only. The ex vivo T cell responses in peripheral blood were detectable for more than one year and could be strongly boosted by a second vaccination. Hence, XS15 is a promising adjuvant candidate for peptide vaccination, in particular for tumor peptide vaccines in a personalized setting.
Identifiants
pubmed: 31730025
doi: 10.1186/s40425-019-0796-5
pii: 10.1186/s40425-019-0796-5
pmc: PMC6858783
doi:
Substances chimiques
Adjuvants, Immunologic
0
Ligands
0
Peptides
0
Toll-Like Receptor 1
0
Toll-Like Receptor 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
307Commentaires et corrections
Type : ErratumIn
Références
JCO Precis Oncol. 2017;2017:null
pubmed: 29951597
Mol Immunol. 2009 Mar;46(6):1084-91
pubmed: 19027958
Rejuvenation Res. 2019 Feb;22(1):31-42
pubmed: 29926769
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Regul Toxicol Pharmacol. 2005 Aug;42(3):265-74
pubmed: 15979222
Nat Med. 2012 Aug;18(8):1254-61
pubmed: 22842478
Cell. 2007 Sep 21;130(6):1071-82
pubmed: 17889651
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
Prostate. 2009 Jun 15;69(9):917-27
pubmed: 19267352
Immunity. 2006 Jun;24(6):767-77
pubmed: 16782032
Eur J Immunol. 1991 Nov;21(11):2649-54
pubmed: 1936113
Vaccine. 2011 Apr 12;29(17):3341-55
pubmed: 20713100
Cytometry A. 2015 Oct;87(10):967-75
pubmed: 26033882
J Immunol. 2005 Apr 1;174(7):4127-34
pubmed: 15778372
Chem Commun (Camb). 2015 May 21;51(41):8574-83
pubmed: 25797909
Leuk Lymphoma. 2017 May;58(5):1246-1249
pubmed: 27852136
Cancer Immunol Immunother. 2013 Jul;62(7):1149-59
pubmed: 23657629
JCI Insight. 2018 Jun 7;3(11):
pubmed: 29875315
Oncoimmunology. 2016 Sep 9;5(10):e1216290
pubmed: 27853637
Clin Cancer Res. 2004 Nov 1;10(21):7207-19
pubmed: 15534094
Front Immunol. 2017 Feb 08;8:96
pubmed: 28228758
J Immunol. 2000 Oct 1;165(7):3804-10
pubmed: 11034386
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):28-35
pubmed: 29465357
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
J Immunol. 2002 May 1;168(9):4531-7
pubmed: 11970999
Oncoimmunology. 2013 Jul 1;2(7):e24743
pubmed: 24073366
Lancet Oncol. 2016 Nov;17(11):1599-1611
pubmed: 27720136
Immunity. 2002 Sep;17(3):289-301
pubmed: 12354382
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Cancer Immunol Immunother. 2017 Jul;66(7):891-901
pubmed: 28391357
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8698-E8706
pubmed: 30150374
Immunity. 2014 Mar 20;40(3):436-50
pubmed: 24656047
Nature. 2017 Nov 23;551(7681):517-520
pubmed: 29132144
J Immunol. 2000 Dec 1;165(11):6538-44
pubmed: 11086096
Cancer Res. 2018 Aug 15;78(16):4627-4641
pubmed: 29789417
Am J Physiol Lung Cell Mol Physiol. 2017 Oct 1;313(4):L651-L658
pubmed: 28839102
Methods Mol Biol. 2013;960:145-157
pubmed: 23329485
Int J Cancer. 2012 Jun 1;130(11):2607-17
pubmed: 21796616
J Autoimmun. 2013 Feb;40:1-8
pubmed: 22890025
Cytometry A. 2015 Jan;87(1):37-48
pubmed: 25297339
EMBO Rep. 2018 Dec;19(12):
pubmed: 30337494
Int J Cancer. 2012 Jul 1;131(1):140-9
pubmed: 21858810
Oncotarget. 2016 Oct 11;7(41):67087-67100
pubmed: 27564262
Cytometry B Clin Cytom. 2018 Mar;94(2):342-353
pubmed: 27363684
J Biol Chem. 2002 Jun 7;277(23):20847-53
pubmed: 11912201
Nature. 1989 Nov 30;342(6249):561-4
pubmed: 2586628
Clin Transl Immunology. 2016 May 20;5(5):e85
pubmed: 27350884
Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918
pubmed: 29644387